Scholars@Duke
Herbert Kim Lyerly

Herbert Kim Lyerly

George Barth Geller Distinguished Professor of Immunology
Surgery, Surgical Sciences
lyerl001@mc.duke.edu
Box 2606 Med Ctr, Durham, NC 27710
203 Research Drive, Rm 433B, Box 2606, Durham, NC 27710

Scholarly Works - Conferences

Ultrasound-Enhanced Dye Penetration in Agar Gel Phantoms Using a Trocar-Integrated Dual-Aperture Ultrasound Transducer

Conference 2025 IEEE 20th Nanotechnology Materials and Devices Conference Nmdc 2025 · January 1, 2025 High interstitial pressure and solid stress in tumors pose significant barriers to effective intratumoral drug delivery. To address this, a 320 kHz ultrasound transducer was integrated into a trocar, featuring dual side-facing acoustic apertures and an inj ... Full text Cite

Abstract B009: Enhancing Antitumor Immune Responses: Trastuzumab Deruxtecan (T- DXd) Induces Immunogenic Cell Death and Phagocytosis, Synergizing with CD47/SIRPα Checkpoint Blockade

Conference Cancer Immunology Research · October 18, 2024 AbstractTrastuzumab deruxtecan (T-DXd), or fam-trastuzumab-deruxtecan-nxki, is a novel antibody-drug conjugate (ADC) targeting HER2 that has demonstrated profound clinical efficacy across HER2-positive breas ... Full text Cite

Abstract A059: Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer.

Conference Cancer Immunology Research · October 18, 2024 AbstractTrastuzumab deruxtecan (T-DXd), or fam-trastuzumab-deruxtecan-nxki, is a novel antibody-drug-conjugate (ADC) targeting HER2 that has demonstrated profound clinical efficacy across HER2-positive breas ... Full text Cite

Abstract PO3-26-06: A self-replicating RNA Precision Immunotherapeutic for Overcoming Resistance to Endocrine Therapy in Estrogen Receptor Positive Breast Cancer (ER+BC)

Conference Cancer Research · May 2, 2024 AbstractAdvanced or metastatic ER+HER2- breast cancer (ER+BC) is an incurable disease. Standard 1L therapy (SOC) utilizes endocrine blockade with a nonsteroidal aromatase inhibitor (NSAI) combined with a CDK ... Full text Cite

Abstract 2458: Targeting the CXCR3 axis in HER2+ breast cancer to enhance anti-tumor immunity

Conference Cancer Research · March 22, 2024 AbstractBreast cancer (BC) is the most frequently diagnosed cancer in women worldwide with more than 2 million new cases in 2020. The efficacy of immunotherapies for BC is limited, with response rates of &am ... Full text Cite

Abstract 3985: Immune-competent “NoGlow” transgenic mice overcome restrictive tolerance to multiple xenoantigens and simultaneously permit identification, tracking, and temporal gene expression in tumor cells

Conference Cancer Research · March 22, 2024 AbstractThe ability to temporally regulate gene expression and track labeled cells make animal models powerful biomedical tools. However, sudden exposure to xenobiotic genes (e.g. GFP, luciferase (luc), or r ... Full text Cite

Abstract 5296: Enhancing the strength and durability of vaccine-induced anti-tumor immunity with CD27 agonism of CD4+ T cells

Conference Cancer Research · March 22, 2024 AbstractDespite encouraging early phase clinical trials, decades of research have yet to yield effective cancer vaccine immunotherapies. To determine potential markers for success, we performed a follow-up s ... Full text Cite

Abstract 2732: A self-replicating RNA precision medicine approach to therapeutic protein delivery of narrow therapeutic index biomolecules

Conference Cancer Research · April 4, 2023 AbstractProtein drug replacement using nucleic acid technologies has been a sought-after solution for in situ production of proteins with poor half-lives and challenging manufacturability. Linear mRNA approa ... Full text Cite

Abstract 6403: A self-replicating RNA precision medicine approach to overcoming resistance to endocrine therapy in ER+BC

Conference Cancer Research · April 4, 2023 AbstractDrug resistance remains the major driving factor behind the clinical failure of targeted therapeutics. Current oncology precision medicine approaches rely on targeting known acquired resistance mutat ... Full text Cite

Abstract 696: Sensitizing breast cancers to immune checkpoint inhibitors through CD27 agonism and vaccination against tumor-associated antigen

Conference Cancer Research · April 4, 2023 AbstractProject objective: Despite the recent revolution in immune checkpoint inhibitors (ICIs), only modest improvement in overall survival and likely caused by not enough potent cellular immunity among BC ... Full text Cite

Abstract PR015: Dormant mammary tumors persist long-term despite adaptive immunity by establishing a Treg-dominated niche via DKK3

Conference Cancer Research · January 15, 2023 AbstractA significant portion of breast cancer survivors eventually experience locoregional or metastatic recurrence. It is clear that the adaptive immune system controls proliferative tumor outgrowth, but h ... Full text Cite

Ultrasound Enhanced Perfusion and Drug Penetration for Intratumoral Immunotherapy Using a Needle Ultrasound Transducer - a Phantom Study

Conference IEEE International Ultrasonics Symposium Ius · January 1, 2023 Intratumoral immunotherapy is a promising cancer treatment approach that can initiate durable anti-tumor responses and avoid potential off-target toxicities. However, direct intratumoral injection remains challenging owing to elevated solid stress and inte ... Full text Cite

Intracorporeal Sonoporation-Induced Drug/Gene Delivery Using a Catheter Ultrasound Transducer

Conference IEEE International Ultrasonics Symposium Ius · January 1, 2022 Ultrasound (US) has been recently demonstrated promising in cancer immunotherapy. By virtue of microbubble-mediated cavitation, US can induce temporary pores in the cell membrane to enhance drug/gene delivery and this process is termed sonoporation. Curren ... Full text Cite

Visualizing Cell Competition and Mechanisms of Occult Tumorigenesis Ex Vivo.

Conference IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL · June 2021 Link to item Cite

Targeting the Glucagon Receptor Signaling Pathway As a Novel Strategy to Counteract PI3K Inhibitor Induced Hyperglycemia While Sustaining Tumor PI3K Inhibition

Conference Blood · November 5, 2020 Pathologic activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway is an oncogenic driver for many malignancies, including lymphomas1. Although validated as a therapeutic oncologic target, the PI3K signaling pathway is also imp ... Full text Cite

Abstract 904: Stimulation and expansion of oncogene-reactive tumor infiltrating T cells through combined Ad-HER2Δ16 vaccination and anti-PD1 enable anti-tumor responses against established HER2 BC

Conference Cancer Research · August 15, 2020 AbstractDespite promising advances, overcoming immune suppression and driving productive immune responses in the tumor microenvironment remains a significant challenge. Using a spontaneous breast cancer mode ... Full text Cite

Abstract B03: Trastuzumab therapy suppresses HER2+ breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade

Conference Cancer Immunology Research · April 1, 2020 AbstractBackground: HER2 overexpression and amplification define ~20% of breast cancers (BC) that are currently treated using HER2-specific monoclonal antibodies (mAb), such as trastuzumab. While multiple st ... Full text Cite

Abstract B107: Dormant breast tumor cells avoid the adaptive immune system through regulation of the immune and tumor microenvironment

Conference Cancer Immunology Research · March 1, 2020 AbstractMany cancer survivors respond to early treatment with complete remission only to succumb to the disease after the tumor returns, sometimes decades later, in a distant metastatic site. Tumor cells can ... Full text Cite

Small Aperture Ultrasound Transducers for Intracavitary Tissue Ablation

Conference IEEE International Ultrasonics Symposium Ius · October 1, 2019 Catheter directed ultrasound (US) transducer is capable of delivering high, focused acoustic power to the target tissue inside a body. The direct interaction with the tissue enables to minimize the concern of unintended tissue damages. Despite the potentia ... Full text Cite

Abstract 4071: A novel combination therapy of high intensity focused ultrasound and PDL1 blockades against advanced breast cancer

Conference Cancer Research · July 1, 2019 AbstractBackground: Previous studies have reported that tumor debris and inflammation made by high-intensity focused ultrasound (HIFU) therapy induced the antitumor immune response, however, HIFU as a monoth ... Full text Cite

Abstract 3731: A novel heat shock protein 90-targeted photosensitizer (HS-201) enables enhanced tumor-specific photodynamic therapy of inflammatory breast cancers

Conference Cancer Research · July 1, 2019 AbstractBackground: Photodynamic therapy (PDT) is an effective local anti-cancer modality applied for the treatment of early stage disease and palliation of advanced disease, and could be used in managing ... Full text Cite

Effector T-cell cytolytic activity modules derived from CD3+ single cells from human primary triple-negative breast cancer (TNBC) in multiple solid tumors to predict response to immune checkpoint blockade therapy (ICB).

Conference Journal of Clinical Oncology · May 20, 2019 1073 Background: The prognostic and predictive value of tumor infiltrating lymphocytes for ICB has been recognized in a variety of tumor types, including TNBC. Nonetheless, our understanding of the mechanistic aspects of T cell a ... Full text Cite

Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients

Conference Cancer Research · February 15, 2019 AbstractBackground: Immune-based therapy for metastatic breast cancer has had limited success. Strategies to augment adaptive immunity include vaccines targeting genomic amplifications like Human Epidermal G ... Full text Cite

Abstract A22: Augmentation of a novel adenoviral vaccine strategy by checkpoint inhibitors

Conference Cancer Immunology Research · September 1, 2018 AbstractThe immunologic hurdles for a vaccine targeting cancer are much higher than for those targeting an infectious disease. The profoundly immunosuppressive tumor microenvironment, the lack of microbial d ... Full text Cite

Abstract B66: Targeted activation of innate immune adaptors MAVS and STING promotes antitumor responses in colorectal cancer models

Conference Cancer Immunology Research · September 1, 2018 AbstractWhile the use of immune checkpoint blockade (ICB) has gained significant traction as a viable therapy for certain cancers, many more cancers remain refractory to immunotherapies due to their highly i ... Full text Cite

Abstract 1859: Hsp90 targeted near infrared molecular imaging to detect mammografically occult invasive lobular breast cancer

Conference Cancer Research · July 1, 2017 AbstractBackground: Early diagnosis of Invasive lobular carcinomas (ILCs) is clinically challenging due to its histopathologic features making it difficult to detect using mammography. Because of the diffuse ... Full text Cite

Abstract 4709: Induction of enhanced tumor-specific immunity by Hsp90 targeted photodynamic therapy (Hsp90-PDT) combined with immune checkpoint inhibition

Conference Cancer Research · July 1, 2017 AbstractBackground: Immunotherapy has become an emerging anti-cancer therapy, as immune checkpoint blockade with PD-1 or PD-L1 inhibition have been active against multiple cancer types. Nonetheless, there re ... Full text Cite

Abstract A38: Checkpoint blockade elicits unique T cell expansion to promote tumor regression

Conference Cancer Immunology Research · March 1, 2017 AbstractWhile PD-1 and CTLA-4 immune checkpoint antibodies have led to durable clinical activity in certain cancers, only a fraction of patients exhibit responses. In these responsive tumors, PD-1 and CTLA-4 ... Full text Cite

Abstract B04: Intralesional vaccination with Ad-MAVS alters the immunosuppressive tumor microenvironment and elicits robust anti-tumor immunity in non-immunogenic cancers

Conference Cancer Immunology Research · March 1, 2017 AbstractBackground and Hypothesis: While the use of immune checkpoint blockade has gained significant traction as a viable therapy for certain cancers, many tumors remain refractory to these immunotherapies ... Full text Cite

Abstract B36: Modulating the tumor microenvironment to enhance cancer immunotherapy by inducing phosphatidylserine expression on the tumor surface

Conference Cancer Immunology Research · March 1, 2017 AbstractBackground and Hypothesis: While immune checkpoint blockade, in particular PD-1 or PD-L1 inhibition, has revolutionized cancer immunotherapy, a significant number of patients with solid tumors fail t ... Full text Cite

Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer

Conference Cancer Research · February 15, 2017 AbstractDespite a lack of unifying drivers in Triple-Negative Breast Cancer (TNBC), our lab and others have uncovered that these cancers have elevated expression of inflammatory genes and immunosuppressive m ... Full text Cite

Abstract 3417: Peripheral CD8+CD28-suppressive T lymphocytes act as a prognosticator among breast cancer patients with adoptive T-cell immunotherapy

Conference Cancer Research · July 15, 2016 AbstractIntroduction: This study aimed to assess the prognostic value of CD8+CD28− T lymphocyte in peripheral blood among breast cancer patients treated with adoptive T lymphocytes immunotherapy. ... Full text Cite

Abstract P4-09-16: A monoclonal antibody with exceptional specificity across major breast cancer subtypes

Conference Cancer Research · February 15, 2016 AbstractBackground: Breast cancer (BC) remains the second leading cause of cancer-related deaths for women in the United States and is recognized to be a heterogeneous disease. Advances in technologies such ... Full text Cite

An Anti-HER2 Nanobody Labeled with 18F Using a Residualizing Label for Assessing HER2 Status

Conference EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING · October 1, 2015 Link to item Cite

Abstract 3212: Metastatic breast cancer cell communication within a pro-dormancy bone marrow niche

Conference Cancer Research · August 1, 2015 AbstractDistant metastases are the major cause of death from breast cancer. In estrogen receptor positive (ER+) breast cancer (BC) in particular, metastatic relapse can occur years after initial treatment, s ... Full text Cite

Early detection of breast cancer using a unique tumor specific antibody

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2015 Link to item Cite

Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.

Conference Molecular Cancer Therapeutics · November 1, 2013 AbstractHsp90 inhibitors have demonstrated unusual selectivity for tumor cells despite its ubiquitous expression. This phenomenon has remained unexplained but could be influenced by ectopically expressed Hsp ... Full text Cite

Abstract 5681: Modulation of Wnt/β-catenin signaling by niclosamide and related derivatives.

Conference Cancer Research · April 15, 2013 AbstractThe Wnt signal transduction pathway is dysregulated in many cancers, including colorectal cancer (CRC) where activating mutations in this pathway occur in over 80% of sporadic colorectal cancers. As ... Full text Cite

Abstract 5298: Two distinctive single nucleotide polymorphisms determine liver metastases responses to docetaxel plus thiotepa for metastatic breast cancer patients.

Conference Cancer Research · April 15, 2013 AbstractThe successful predictively treatment of metastatic breast cancer (MBC) remains a major challenge. Until now there is no definite marker to distinguish responder from non-responder and more and more ... Full text Cite

Abstract LB-164: Treatment of advanced stage colorectal cancer with ETBX-011 immunotherapeutic.

Conference Cancer Research · April 15, 2013 AbstractIn this Phase 1/2a non-randomized study, 32 patients having advanced stage metastatic colorectal cancer (mCRC) were treated with a novel immunotherapeutic, ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)). The tri ... Full text Cite

A molecular profile of colorectal cancer to guide prognosis and therapy after resection of primary or metastatic disease.

Conference Journal of Clinical Oncology · February 1, 2013 339 Background: Biomarkers used to identify patients at high risk for recurrence after surgical resection of colorectal cancer (CRC) lack predictive capacity and are applicable only to localized disease. As the use of adjuvant th ... Full text Cite

Development of an assay to predict oxaliplatin sensitivity from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissues.

Conference Journal of Clinical Oncology · February 1, 2011 429 Background: Genomic profiling has improved our understanding of the underlying biology of tumors, accuracy of diagnosing disease, predictions of the courses of disease, and ability to determine the therapeutic agents that wil ... Full text Cite

Impact of a psychosocial intervention on performance status and coping

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2009 Link to item Cite

E/Tablets to collect research-quality, patient-reported data

Conference Journal of Clinical Oncology · May 20, 2008 Full text Cite

Targeting hedgehog signaling in medulloblastoma

Conference NEURO-ONCOLOGY · October 1, 2007 Link to item Cite

E-tablets to collect research-quality patient-reported data

Conference JOURNAL OF CLINICAL ONCOLOGY · June 20, 2007 Link to item Cite

Safety profile of therapeutic pox virus-based vaccines for cancer.

Conference JOURNAL OF CLINICAL ONCOLOGY · July 15, 2004 Link to item Cite

Thoracic paravertebral blockade for ambulatory breast cancer surgery

Conference BREAST CANCER RESEARCH AND TREATMENT · January 1, 2004 Link to item Cite

Magnitude and duration of antigen-specific immune response may affect clinical response

Conference Cancer Immunology Immunotherapy · December 1, 2003 Cite

Dendritic cell (DC) reconstitution after nonmyeloablative allogeneic stem cell transplants

Conference Blood · December 1, 2000 Non-myeloablative allogeneic peripheral blood stem cell transplants {mini-allo PBSCT) are being evaluated as a lower toxicity alternative to conventional allogeneic transplantation for harnessing graft versus tumor effects. Induction of anti-tumor immunity ... Cite

Cancer immunotherapy with tumor RNA transfected dendritic cell vaccines.

Conference JOURNAL OF LEUKOCYTE BIOLOGY · January 1, 1998 Link to item Cite

DIRECT GENE-TRANSFER AND MOLECULAR INTERVENTIONS FOR AIDS AND CANCER

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · August 1, 1994 Link to item Cite

TRANSDOMINANT REV PROTEIN INHIBITS HIV REPLICATION WITHOUT AFFECTING T-CELL FUNCTION

Conference JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY · June 1, 1993 Link to item Cite

DIRECT GENE-TRANSFER AND MOLECULAR INTERVENTIONS FOR AIDS AND CANCER

Conference JOURNAL OF CELLULAR BIOCHEMISTRY · March 29, 1993 Link to item Cite

PH-INDEPENDENT HIV-1 ENTRY INTO MACROPHAGE

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · May 1, 1992 Link to item Cite

THE ENVELOPE V3 LOOP IS THE PRIMARY DETERMINANT OF CELL TROPISM IN HIV-1

Conference AIDS RESEARCH AND HUMAN RETROVIRUSES · May 1, 1992 Link to item Cite

TYPE SPECIFIC BINDING OF SURFACE EXPRESSED GP120 BY ANTI-GP120 SERUM

Conference JOURNAL OF CELLULAR BIOCHEMISTRY · January 1, 1987 Link to item Cite